Integra LifeSciences Holdings Corp (IART) stock
Close on Nov 17, 2026Market cap $1.05BP/E 79.7Yield –
Earnings
Integra LifeSciences's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Integra LifeSciences's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Feb 25, 2027Expected | – | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Oct 21, 2026before the open | $411.20M | +2.3% | $0.19 | $0.59 | Release |
| Q2 FY2026ended Jun 30, 2026 | Jul 29, 2026before the open | $418.80M | +0.8% | $0.06 | $0.56 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 5, 2026before the open | $391.90M | +2.4% | -$0.06 | $0.54 | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 26, 2026before the open | $434.90M | -1.7% | -$0.02 | $0.83 | Release |
| Q3 FY2025ended Sep 30, 2025 | Oct 30, 2025before the open | $402.10M | +5.6% | -$0.07 | $0.54 | Release |
| Q2 FY2025ended Jun 30, 2025 | Jul 31, 2025before the open | $415.60M | -0.6% | -$6.31 | $0.45 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 5, 2025before the open | $382.70M | +3.7% | -$0.33 | $0.41 | Release |
| Q4 FY2024ended Dec 31, 2024 | Feb 25, 2025before the open | $442.60M | +11.5% | $0.25 | $0.97 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 4, 2024before the open | $380.80M | -0.4% | -$0.14 | $0.41 | Release |
| Q2 FY2024ended Jun 30, 2024 | Jul 29, 2024before the open | $418.20M | +9.7% | -$0.16 | $0.63 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 6, 2024before the open | $368.90M | -3.1% | -$0.04 | $0.55 | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 28, 2024before the open | $397.00M | -0.3% | $0.25 | $0.89 | Release |
| Q3 FY2023ended Sep 30, 2023 | Oct 25, 2023before the open | $382.40M | -0.7% | $0.24 | $0.76 | Release |
| Q2 FY2023ended Jun 30, 2023 | Jul 27, 2023after the close | $381.30M | -4.1% | $0.05 | $0.71 | Release |
| Q1 FY2023ended Mar 31, 2023 | Apr 26, 2023before the open | $380.80M | +1.1% | $0.29 | $0.74 | Release |
| Q4 FY2022ended Dec 31, 2022 | Feb 22, 2023before the open | $398.00M | -1.8% | $0.63 | $0.94 | Release |
| Q3 FY2022ended Sep 30, 2022 | Oct 26, 2022before the open | $385.20M | -0.4% | $0.60 | $0.86 | Release |
| Q2 FY2022ended Jun 30, 2022 | Jul 27, 2022before the open | $397.80M | – | $0.54 | $0.82 | Release |
| Q1 FY2022ended Mar 31, 2022 | Apr 27, 2022before the open | $376.60M | – | $0.39 | $0.74 | Release |
| Q4 FY2021ended Dec 31, 2021 | Feb 23, 2022before the open | $405.50M | – | $0.53 | $0.84 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 2, 2021before the open | $386.90M | – | $0.51 | $0.86 | Release |
| Q2 FY2021ended Jun 30, 2021 | Jul 28, 2021before the open | – | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | Apr 28, 2021before the open | – | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Jan 14, 2021before the open | – | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Oct 6, 2020after the close | – | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Integra LifeSciences's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| organic declinenon-GAAP | Q4 FY2026 | -5.1% – -0.4% | – | New | Oct 21, 2026 |
| reported revenuesGAAP | Q4 FY2026 | $413.00M – $433.00M | – | New | Oct 21, 2026 |
| adjusted earnings per diluted sharenon-GAAP | Q4 FY2026 | $0.61 – $0.71 | – | New | Oct 21, 2026 |
| organic growthnon-GAAP | FY2026 | -0.3% – +0.9% | – | New | Oct 21, 2026 |
| organic growthnon-GAAP | FY2026 | +0.8% – +3.3% | +0.8% – +3.3% | Reaffirmed | May 5, 2026 |
| reported growth | FY2026 | +1.6% – +4.1% | +1.6% – +4.1% | Reaffirmed | May 5, 2026 |
| reported revenue outlookGAAP | FY2026 | $1.65B – $1.70B | – | New | Jul 29, 2026 |
| revenue guidance | FY2026 | $1.66B – $1.70B | $1.66B – $1.70B | Reaffirmed | May 5, 2026 |
| revenuesGAAP | FY2026 | $1.63B – $1.65B | – | New | Oct 21, 2026 |
| adjusted earnings per diluted sharenon-GAAP | FY2026 | $2.30 – $2.40 | – | New | Oct 21, 2026 |
| adjusted earnings per sharenon-GAAP | FY2026 | $2.40 – $2.50 | $2.40 – $2.50 | Reaffirmed | Jul 29, 2026 |
| operating cash flowGAAP | FY2026 | $190.00M – $200.00M | – | New | Oct 21, 2026 |
| organic revenue growthnon-GAAP | FY2026 | +0.8% – +3.3% | – | New | Jul 29, 2026 |
Guidance vs results
The last range Integra LifeSciences gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| Q3 FY2026 | adjusted EPS | $0.53 – $0.61 | $0.59 | Within range |
| Q3 FY2026 | Revenue | $410.00M – $425.00M | $411.20M | Within range |
| Q2 FY2026 | adjusted EPS | $0.44 – $0.52 | $0.56 | Above range |
| Q2 FY2026 | Revenue | $410.00M – $425.00M | $418.80M | Within range |
| Q2 FY2026 | Revenue growth | -1.3% – +2.3% | +0.77% | Within range |
| Q1 FY2026 | Adjusted earnings per diluted share | $0.37 – $0.45 | $0.54 | Above range |
| Q1 FY2026 | Revenue | $375.00M – $390.00M | $391.90M | Above range |
| Q1 FY2026 | Revenue growth | -2% – +1.9% | +2.4% | Above range |
| FY2025 | adjusted EPS | $2.19 – $2.24 | $2.23Σ4Q | Within range |
| FY2025 | Revenue | $1.62B – $1.64B | $1.64BΣ4Q | Within range |
| FY2025 | Revenue growth | +0.6% – +1.8% | +1.54%Σ4Q | Within range |
| Q4 FY2025 | adjusted EPS | $0.79 – $0.84 | $0.83 | Within range |
| Q4 FY2025 | Revenue | $420.00M – $440.00M | $434.90M | Within range |
| Q4 FY2025 | Revenue growth | -5.1% – -0.6% | -1.74% | Within range |
| Q3 FY2025 | adjusted EPS | $0.40 – $0.45 | $0.54 | Above range |
| Q3 FY2025 | Revenue | $410.00M – $420.00M | $402.10M | Below range |
| Q3 FY2025 | Revenue growth | +7.7% – +10.3% | +5.59% | Below range |
| Q2 FY2025 | adjusted EPS | $0.40 – $0.45 | $0.45 | Within range |
| Q2 FY2025 | Revenue | $390.00M – $400.00M | $415.60M | Above range |
| Q1 FY2025 | Adjusted earnings per diluted share | $0.40 – $0.45 | $0.41 | Within range |
| Q1 FY2025 | Revenue | $375.00M – $385.00M | $382.70M | Within range |
| Q1 FY2025 | Revenue growth | +1.6% – +4.4% | +3.74% | Within range |
| Q4 FY2024 | adjusted EPS | $0.81 – $0.89 | $0.97 | Above range |
| Q4 FY2024 | Revenue | $441.00M – $451.00M | $442.60M | Within range |
| Q4 FY2024 | Revenue growth | +11.1% – +13.6% | +11.49% | Within range |
| Q3 FY2024 | adjusted EPS | $0.36 – $0.44 | $0.41 | Within range |
| Q3 FY2024 | Revenue | $372.00M – $382.00M | $380.80M | Within range |
| Q2 FY2024 | Adjusted earnings per diluted share | $0.60 – $0.65 | $0.63 | Within range |
| Q2 FY2024 | Revenue | $411.00M – $416.00M | $418.20M | Above range |
| Q1 FY2024 | Adjusted earnings per diluted share | $0.53 – $0.57 | $0.55 | Within range |
| Q1 FY2024 | Revenue | $360.00M – $365.00M | $368.90M | Above range |
| Q4 FY2023 | Adjusted earnings per diluted share | $0.89 – $0.93 | $0.89 | Within range |
| Q4 FY2023 | Revenue | $397.00M – $403.00M | $397.00M | Within range |
| Q3 FY2023 | Adjusted earnings per diluted share | $0.76 – $0.80 | $0.76 | Within range |
| Q3 FY2023 | Revenue | $386.00M – $390.00M | $382.40M | Below range |
| Q2 FY2023 | Adjusted earnings per diluted share | $0.75 – $0.79 | $0.71 | Below range |
| Q2 FY2023 | Revenue | $396.00M – $400.00M | $381.30M | Below range |
| Q1 FY2023 | Adjusted earnings per diluted share | $0.72 – $0.76 | $0.74 | Within range |
| Q1 FY2023 | Revenue | $370.00M – $376.00M | $380.80M | Above range |
| Q4 FY2022 | Adjusted earnings per diluted share | $0.87 – $0.91 | $0.94 | Above range |
| Q4 FY2022 | Revenue | $391.00M – $403.00M | $398.00M | Within range |
| Q3 FY2022 | Adjusted earnings per diluted share | $0.78 – $0.82 | $0.86 | Above range |
| Q3 FY2022 | Revenue | $383.00M – $391.00M | $385.20M | Within range |
| Q2 FY2022 | Adjusted earnings per diluted share | $0.78 – $0.82 | $0.82 | Within range |
| Q2 FY2022 | Revenue | $392.00M – $400.00M | $397.80M | Within range |
| Q1 FY2022 | Adjusted earnings per diluted share | $0.67 – $0.71 | $0.74 | Above range |
| Q1 FY2022 | Revenue | $357.00M – $365.00M | $376.60M | Above range |
| Q4 FY2021 | Adjusted earnings per diluted share | $0.82 – $0.86 | $0.84 | Within range |
| Q4 FY2021 | Revenue | $403.00M | $405.50M | Above range |
Guidance history
Every forecast Integra LifeSciences put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Oct 21, 2026 | adjusted earnings per diluted share | Q4 FY2026 | $0.61 – $0.71 | New |
| Oct 21, 2026 | adjusted earnings per diluted share | FY2026 | $2.30 – $2.40 | New |
| Oct 21, 2026 | operating cash flow | FY2026 | $190.00M – $200.00M | New |
| Oct 21, 2026 | organic decline | Q4 FY2026 | -5.1% – -0.4% | New |
| Oct 21, 2026 | reported revenues | Q4 FY2026 | $413.00M – $433.00M | New |
| Oct 21, 2026 | organic growth | FY2026 | -0.3% – +0.9% | New |
| Oct 21, 2026 | revenues | FY2026 | $1.63B – $1.65B | New |
| Jul 29, 2026 | adjusted earnings per share | FY2026 | $2.40 – $2.50 | Reaffirmed |
| Jul 29, 2026 | adjusted EPS | Q3 FY2026 | $0.53 – $0.61 | New |
| Jul 29, 2026 | organic revenue growth | FY2026 | +0.8% – +3.3% | New |
| Jul 29, 2026 | reported growth | Q3 FY2026 | +2% – +5.7% | New |
| Jul 29, 2026 | organic growth | Q3 FY2026 | +1.9% – +5.7% | New |
| Jul 29, 2026 | reported revenue outlook | FY2026 | $1.65B – $1.70B | New |
| Jul 29, 2026 | reported revenues | Q3 FY2026 | $410.00M – $425.00M | New |
| May 5, 2026 | adjusted EPS | FY2026 | $2.40 – $2.50 | Raised |
| May 5, 2026 | adjusted EPS | Q2 FY2026 | $0.44 – $0.52 | New |
| May 5, 2026 | reported growth | FY2026 | +1.6% – +4.1% | Reaffirmed |
| May 5, 2026 | organic growth | FY2026 | +0.8% – +3.3% | Reaffirmed |
| May 5, 2026 | revenue guidance | FY2026 | $1.66B – $1.70B | Reaffirmed |
| May 5, 2026 | reported growth | Q2 FY2026 | -1.3% – +2.3% | New |
| May 5, 2026 | organic growth | Q2 FY2026 | -1.5% – +2.1% | New |
| May 5, 2026 | reported revenues | Q2 FY2026 | $410.00M – $425.00M | New |
| Feb 26, 2026 | Adjusted earnings per diluted share | FY2026 | $2.30 – $2.40 | New |
| Feb 26, 2026 | Adjusted earnings per diluted share | Q1 FY2026 | $0.37 – $0.45 | New |
| Feb 26, 2026 | reported growth | FY2026 | +1.6% – +4.1% | New |
| Feb 26, 2026 | organic growth | FY2026 | +0.8% – +3.3% | New |
| Feb 26, 2026 | revenues | FY2026 | $1.66B – $1.70B | New |
| Feb 26, 2026 | reported growth | Q1 FY2026 | -2% – +1.9% | New |
| Feb 26, 2026 | organic growth | Q1 FY2026 | -3.4% – +0.5% | New |
| Feb 26, 2026 | reported revenues | Q1 FY2026 | $375.00M – $390.00M | New |
| Oct 30, 2025 | adjusted EPS | FY2025 | $2.19 – $2.24 | New |
| Oct 30, 2025 | adjusted EPS | Q4 FY2025 | $0.79 – $0.84 | New |
| Oct 30, 2025 | reported growth | FY2025 | +0.6% – +1.8% | New |
| Oct 30, 2025 | organic growth | FY2025 | -1.6% – -0.4% | New |
| Oct 30, 2025 | revenue guidance range | FY2025 | $1.62B – $1.64B | New |
| Oct 30, 2025 | reported growth | Q4 FY2025 | -5.1% – -0.6% | New |
| Oct 30, 2025 | organic growth | Q4 FY2025 | -5.9% – -1.4% | New |
| Oct 30, 2025 | reported revenues | Q4 FY2025 | $420.00M – $440.00M | New |
| Jul 31, 2025 | adjusted EPS | Q3 FY2025 | $0.40 – $0.45 | New |
| Jul 31, 2025 | adjusted EPS guidance range | FY2025 | $2.19 – $2.29 | Reaffirmed |
| Jul 31, 2025 | reported growth | Q3 FY2025 | +7.7% – +10.3% | New |
| Jul 31, 2025 | organic growth | Q3 FY2025 | +7.3% – +9.9% | New |
| Jul 31, 2025 | reported revenues | Q3 FY2025 | $410.00M – $420.00M | New |
| Jul 31, 2025 | reported growth | FY2025 | +2.8% – +4.3% | Narrowed |
| Jul 31, 2025 | organic growth | FY2025 | +0.6% – +2.1% | Lowered |
| Jul 31, 2025 | revenue guidance range | FY2025 | $1.66B – $1.68B | Narrowed |
| May 5, 2025 | adjusted EPS | Q2 FY2025 | $0.40 – $0.45 | New |
| May 5, 2025 | adjusted EPS guidance | FY2025 | $2.19 – $2.29 | Lowered |
| May 5, 2025 | reported revenues | Q2 FY2025 | $390.00M – $400.00M | New |
| May 5, 2025 | revenue guidance ranges | FY2025 | $1.65B – $1.72B | Reaffirmed |
| Feb 25, 2025 | Adjusted earnings per diluted share | Q1 FY2025 | $0.40 – $0.45 | New |
| Feb 25, 2025 | Adjusted earnings per diluted share | FY2025 | $2.41 – $2.51 | New |
| Feb 25, 2025 | reported growth | Q1 FY2025 | +1.6% – +4.4% | New |
| Feb 25, 2025 | organic growth | Q1 FY2025 | -6.2% – -3.5% | New |
| Feb 25, 2025 | reported revenues | Q1 FY2025 | $375.00M – $385.00M | New |
| Feb 25, 2025 | reported growth | FY2025 | +2.4% – +6.5% | New |
| Feb 25, 2025 | organic growth | FY2025 | +1% – +5% | New |
| Feb 25, 2025 | revenues | FY2025 | $1.65B – $1.72B | New |
| Nov 4, 2024 | adjusted EPS | Q4 FY2024 | $0.81 – $0.89 | New |
| Nov 4, 2024 | adjusted EPS | FY2024 | $2.41 – $2.49 | Lowered |
| Nov 4, 2024 | reported growth | Q4 FY2024 | +11.1% – +13.6% | New |
| Nov 4, 2024 | organic growth | Q4 FY2024 | +2% – +4.5% | New |
| Nov 4, 2024 | reported revenues | Q4 FY2024 | $441.00M – $451.00M | New |
| Nov 4, 2024 | reported growth | FY2024 | +4.4% – +5% | New |
| Nov 4, 2024 | organic growth | FY2024 | -1.7% – -1% | Lowered |
| Nov 4, 2024 | revenue | FY2024 | $1.61B – $1.62B | New |
| Jul 29, 2024 | adjusted EPS | Q3 FY2024 | $0.36 – $0.44 | New |
| Jul 29, 2024 | adjusted EPS | FY2024 | $2.41 – $2.57 | Lowered |
| Jul 29, 2024 | organic growth | Q3 FY2024 | -9.4% – -6.7% | New |
| Jul 29, 2024 | reported revenues | Q3 FY2024 | $372.00M – $382.00M | New |
| Jul 29, 2024 | organic growth | FY2024 | -1% – +0.3% | Lowered |
| Jul 29, 2024 | revenue | FY2024 | $1.61B – $1.63B | Lowered |
| May 6, 2024 | Adjusted earnings per diluted share | Q2 FY2024 | $0.60 – $0.65 | New |
| May 6, 2024 | adjusted EPS | FY2024 | $3.01 – $3.11 | Lowered |
| May 6, 2024 | organic growth | Q2 FY2024 | +1.3% – +2.6% | New |
| May 6, 2024 | reported revenues | Q2 FY2024 | $411.00M – $416.00M | New |
| May 6, 2024 | organic growth | FY2024 | +3.3% – +4.3% | Lowered |
| May 6, 2024 | revenue | FY2024 | $1.67B – $1.69B | Raised |
| Feb 28, 2024 | Adjusted earnings per diluted share | Q1 FY2024 | $0.53 – $0.57 | New |
| Feb 28, 2024 | Adjusted earnings per diluted share | FY2024 | $3.15 – $3.25 | New |
| Feb 28, 2024 | organic growth | Q1 FY2024 | -5.1% – -3.7% | New |
| Feb 28, 2024 | reported revenues | Q1 FY2024 | $360.00M – $365.00M | New |
| Feb 28, 2024 | organic growth | FY2024 | +4% – +5% | New |
| Feb 28, 2024 | revenues | FY2024 | $1.60B – $1.62B | New |
| Oct 25, 2023 | Adjusted earnings per diluted share | Q4 FY2023 | $0.89 – $0.93 | New |
| Oct 25, 2023 | adjusted EPS | FY2023 | $3.10 – $3.14 | Lowered |
| Oct 25, 2023 | organic growth | Q4 FY2023 | -0.8% – +0.7% | New |
| Oct 25, 2023 | reported revenues | Q4 FY2023 | $397.00M – $403.00M | New |
| Oct 25, 2023 | organic growth | FY2023 | +0.1% – +0.5% | Lowered |
| Oct 25, 2023 | revenue | FY2023 | $1.54B – $1.55B | Lowered |
| Jul 26, 2023 | Adjusted earnings per diluted share | Q3 FY2023 | $0.76 – $0.80 | New |
| Jul 26, 2023 | adjusted EPS | FY2023 | $3.10 – $3.18 | Lowered |
| Jul 26, 2023 | organic growth | FY2023 | +0.3% – +1.1% | Lowered |
| Jul 26, 2023 | organic growth | Q3 FY2023 | +0.3% – +1.3% | New |
| Jul 26, 2023 | revenue | FY2023 | $1.55B – $1.56B | Lowered |
| Jul 26, 2023 | reported revenues | Q3 FY2023 | $386.00M – $390.00M | New |
| Apr 26, 2023 | adjusted EPS | FY2023 | $3.43 – $3.51 | Reaffirmed |
| Apr 26, 2023 | Adjusted earnings per diluted share | Q2 FY2023 | $0.75 – $0.79 | New |
| Apr 26, 2023 | reported revenues | Q2 FY2023 | $396.00M – $400.00M | New |
| Apr 26, 2023 | organic growth | FY2023 | +4% – +5.2% | Reaffirmed |
| Apr 26, 2023 | organic growth | Q2 FY2023 | +1.5% – +2.5% | New |
| Apr 26, 2023 | revenue | FY2023 | $1.60B – $1.62B | Reaffirmed |
| Feb 22, 2023 | Adjusted earnings per diluted share | Q1 FY2023 | $0.72 – $0.76 | New |
| Feb 22, 2023 | Adjusted earnings per diluted share | FY2023 | $3.43 – $3.51 | New |
| Feb 22, 2023 | organic growth | Q1 FY2023 | +2% – +3.5% | New |
| Feb 22, 2023 | reported revenues | Q1 FY2023 | $370.00M – $376.00M | New |
| Feb 22, 2023 | organic growth | FY2023 | +4% – +5.2% | New |
| Feb 22, 2023 | revenues | FY2023 | $1.60B – $1.62B | New |
| Oct 26, 2022 | Adjusted earnings per diluted share | Q4 FY2022 | $0.87 – $0.91 | New |
| Oct 26, 2022 | adjusted EPS | FY2022 | $3.29 – $3.33 | Raised |
| Oct 26, 2022 | organic growth | Q4 FY2022 | +1.3% – +4.3% | New |
| Oct 26, 2022 | reported revenues | Q4 FY2022 | $391.00M – $403.00M | New |
| Oct 26, 2022 | organic growth | FY2022 | +3.7% – +4.5% | Lowered |
| Oct 26, 2022 | revenue expectations | FY2022 | $1.55B – $1.56B | Lowered |
| Jul 27, 2022 | Adjusted earnings per diluted share | Q3 FY2022 | $0.78 – $0.82 | New |
| Jul 27, 2022 | adjusted earnings per diluted share | FY2022 | $3.21 – $3.29 | Lowered |
| Jul 27, 2022 | organic growth | Q3 FY2022 | +2.6% – +4.8% | New |
| Jul 27, 2022 | reported revenues | Q3 FY2022 | $383.00M – $391.00M | New |
| Jul 27, 2022 | organic growth | FY2022 | +4% – +5.2% | Raised |
| Jul 27, 2022 | reported revenue | FY2022 | $1.56B – $1.58B | Lowered |
| Apr 27, 2022 | Adjusted earnings per diluted share | Q2 FY2022 | $0.78 – $0.82 | New |
| Apr 27, 2022 | adjusted earnings per diluted share guidance | FY2022 | $3.27 – $3.35 | Reaffirmed |
| Apr 27, 2022 | organic growth | Q2 FY2022 | +2.8% – +4.8% | New |
| Apr 27, 2022 | reported revenues | Q2 FY2022 | $392.00M – $400.00M | New |
| Apr 27, 2022 | organic growth expectations | FY2022 | +3.8% – +5.2% | Raised |
| Apr 27, 2022 | reported revenue guidance | FY2022 | $1.58B – $1.60B | Reaffirmed |
| Feb 23, 2022 | Adjusted earnings per diluted share | Q1 FY2022 | $0.67 – $0.71 | New |
| Feb 23, 2022 | Adjusted earnings per diluted share | FY2022 | $3.27 – $3.35 | New |
| Feb 23, 2022 | organic growth | Q1 FY2022 | 0% – +2.5% | New |
| Feb 23, 2022 | reported revenues | Q1 FY2022 | $357.00M – $365.00M | New |
| Feb 23, 2022 | organic growth | FY2022 | +3.5% – +5% | New |
| Feb 23, 2022 | revenues | FY2022 | $1.58B – $1.60B | New |
| Nov 2, 2021 | Adjusted earnings per diluted share | Q4 FY2021 | $0.82 – $0.86 | New |
| Nov 2, 2021 | adjusted earnings per share | FY2021 | $3.16 – $3.20 | New |
| Nov 2, 2021 | organic growth | Q4 FY2021 | +6.5% | New |
| Nov 2, 2021 | revenue | Q4 FY2021 | $403.00M | New |
| Nov 2, 2021 | revenue guidance | FY2021 | $1.54B – $1.55B | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Integra LifeSciences filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Update
- Integra LifeSciences Announces Preliminary Third Quarter Results and Updates Full-Year 2026 GuidanceResults
- Update
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Update
- Results
See a number that looks wrong?